sinc
outbreak
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
expans
endem
epidem
coronavirus
acceler
scale
seen
group
virus
pandem
potenti
past
two
decad
alon
five
new
human
coronavirus
discov
three
highli
pathogen
coronaviru
diseas
pandem
latest
exampl
danger
pose
zoonot
diseas
foreshadow
region
unab
emerg
middl
east
respiratori
syndrom
corona
viru
merscov
recognit
intrins
threat
public
health
prototyp
member
famili
coronavirida
prioritis
merscov
pathogen
increas
resourc
dedic
countermeasur
research
develop
newli
establish
coalit
epidem
prepared
innov
follow
suit
invest
develop
candid
merscov
vaccin
subsequ
year
three
vaccin
candid
complet
initi
clinic
evalu
readi
advanc
test
lancet
infecti
diseas
two
group
report
result
phase
clinic
trial
nonrepl
viral
vector
merscov
vaccin
pedro
folegatti
colleagu
summaris
safeti
immunogen
chimpanze
adenovirusvector
vaccin
mer
till
koch
colleagu
poxvirusvector
vaccin
mvamerss
two
vaccin
demonstr
toler
safeti
profil
vaccinerel
seriou
advers
event
report
either
vaccin
induc
humor
cellular
immun
respons
peak
postvaccin
timepoint
mer
administ
singl
inject
wherea
mvamerss
given
twodos
regimen
interv
dose
product
test
doseescal
design
although
frequenc
sever
advers
event
proport
vaccin
dose
studi
higher
dose
mer
improv
immunogen
singl
dose
mer
also
show
earlier
ascent
slower
decay
antibodymedi
cellmedi
immun
although
question
applic
mani
virus
answer
question
elus
among
coronavirus
without
previou
identif
potenti
correl
protect
becom
difficult
ascertain
relev
immunogen
output
second
remain
lack
consensu
methodolog
immunogen
output
measur
although
two
trial
report
similar
assess
humor
responsesbind
antibodi
wildtyp
mer
viru
pseudoviru
neutralis
assaysit
difficult
know
individu
result
compar
studi
koch
colleagu
found
strong
correl
bind
neutralis
antibodi
titr
spearman
correl
ci
wherea
folegatti
colleagu
spearman
repres
immunolog
relev
differ
vaccineinduc
respons
methodolog
differ
laboratori
final
anim
studi
suggest
certain
sarscov
merscov
vaccin
might
upon
viral
challeng
associ
eosinophil
pulmonari
infiltr
find
underscor
import
factor
safeti
design
monitor
longterm
followup
coronaviru
vaccin
trialssometh
fulli
address
two
earlystag
report
see
http
wwwwhoint
blueprintaboutrdblueprint
planofactionpdf
vaccin
candid
see
http
brightoncollabor
mer
vaccin
trial
herein
undoubtedli
consid
futur
efficaci
trial
experi
sar
emerg
mer
particularli
outbreak
arabian
korean
peninsula
harbing
consequ
similar
pathogen
sector
societynot
overal
morbid
mortal
also
capac
level
economi
disrupt
social
order
mer
eclips
pandem
cousin
lesson
learn
prepar
global
vaccin
research
develop
commun
move
coronaviru
vaccin
forward
acceler
pace
firstinhuman
vaccin
trial
move
unpreced
shorten
timelin
stay
ahead
increasingli
frequent
outbreak
field
must
maintain
momentum
advanc
rapid
scalabl
translat
vaccin
strategi
merscov
even
urgent
ultim
next
novel
coronaviru
leap
anim
host
human
